Web-based Application for the Population Pharmacokinetic Service (WAPPS)'s impact on dosage selection: a single paediatric centre experience

1 Iorio A, Marchesini E, Marcucci M, Stobart K, Chan AK. Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B. Cochrane Database Syst Rev 2011; (9): CD003429. doi: 10.1002/14651858.CD003429.pub4. IorioA MarchesiniE MarcucciM StobartK ChanAK Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B Cochrane Database Syst Rev 2011 9 CD003429 10.1002/14651858.CD003429.pub4 Open DOISearch in Google Scholar

2 Valentino LA, Mamonov V, Hellmann A, et al. A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management. J Thromb Haemost 2012; 10(3): 359–67. doi: 10.1111/j.1538-7836.2011.04611.x. ValentinoLA MamonovV HellmannA A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management J Thromb Haemost 2012 10 3 359 67 10.1111/j.1538-7836.2011.04611.x Open DOISearch in Google Scholar

3 Collins PW, Bjorkman S, Fischer K, et al. Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe hemophilia A: influences of variance in pharmacokinetics and treatment regimens. J Thromb Haemost 2010; 8(2): 269–75. doi: 10.1111/j.1538-7836.2009.03703.x. CollinsPW BjorkmanS FischerK Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe hemophilia A: influences of variance in pharmacokinetics and treatment regimens J Thromb Haemost 2010 8 2 269 75 10.1111/j.1538-7836.2009.03703.x Open DOISearch in Google Scholar

4 Björkman S, Folkesson A, Jönsson S. Pharmacokinetics and dose requirements of factor VIII over the age range 3–74 years. Eur J Clin Pharmacol 2009; 65(10): 989–98. doi: 10.1007/s00228-009-0676-x. BjörkmanS FolkessonA JönssonS Pharmacokinetics and dose requirements of factor VIII over the age range 3–74 years Eur J Clin Pharmacol 2009 65 10 989 98 10.1007/s00228-009-0676-x Open DOISearch in Google Scholar

5 Iorio A, Keepanasseril A, Foster G, et al. Development of a Web-Accessible Population Pharmacokinetic Service-Hemophilia (WAPPS-Hemo): Study Protocol. JMIR Res Protoc 2016; 5(4): e239. doi: 10.2196/resprot.6558. IorioA KeepanasserilA FosterG Development of a Web-Accessible Population Pharmacokinetic Service-Hemophilia (WAPPS-Hemo): Study Protocol JMIR Res Protoc 2016 5 4 e239 10.2196/resprot.6558 Open DOISearch in Google Scholar

6 Feldman BM, Pai M, Rivard GE, et al. Tailored prophylaxis in severe hemophilia A: interim results from the first 5 years of the Canadian Hemophilia Primary Prophylaxis Study. J Thromb Haemost 2006; 4(6): 1228–36. doi: 10.1111/j.1538-7836.2006.01953.x. FeldmanBM PaiM RivardGE Tailored prophylaxis in severe hemophilia A: interim results from the first 5 years of the Canadian Hemophilia Primary Prophylaxis Study J Thromb Haemost 2006 4 6 1228 36 10.1111/j.1538-7836.2006.01953.x Open DOISearch in Google Scholar

7 Nagao A, Yeung CHT, Germini F, Suzuki T. Clinical outcomes in hemophilia A patients undergoing tailoring of prophylaxis based on population-based pharmacokinetic dosing. Thromb Res 2019; 173: 79–84. doi: 10.1016/j.thromres.2018.11.017. NagaoA YeungCHT GerminiF SuzukiT Clinical outcomes in hemophilia A patients undergoing tailoring of prophylaxis based on population-based pharmacokinetic dosing Thromb Res 2019 173 79 84 10.1016/j.thromres.2018.11.017 Open DOISearch in Google Scholar

8 Croteau SE, Wheeler AP, Khan O, et al. Pharmacokinetic-tailored approach to hemophilia prophylaxis: Medical decision making and outcomes. Res Pract Thromb Haemost 2020; 4(2): 326–33. doi: 10.1002/rth2.12305. CroteauSE WheelerAP KhanO Pharmacokinetic-tailored approach to hemophilia prophylaxis: Medical decision making and outcomes Res Pract Thromb Haemost 2020 4 2 326 33 10.1002/rth2.12305 Open DOISearch in Google Scholar

9 Stemberger M, Kallenbach F, Schmit E, et al. Impact of adopting population pharmacokinetics for tailoring prophylaxis in haemophilia A patients: a historically controlled observational study. Thromb Haemost 2019; 119(3): 368–76. doi: 10.1055/s-0039-1677700. StembergerM KallenbachF SchmitE Impact of adopting population pharmacokinetics for tailoring prophylaxis in haemophilia A patients: a historically controlled observational study Thromb Haemost 2019 119 3 368 76 10.1055/s-0039-1677700 Open DOISearch in Google Scholar

10 Pasca S, Milan M, Sarolo L, Zanon E. PK-driven prophylaxis versus standard prophylaxis: When a tailored treatment may be a real and achievable cost-saving approach in children with severe hemophilia A. Thromb Res 2017; 157: 58–63. doi: 10.1016/j.thromres.2017.07.003. PascaS MilanM SaroloL ZanonE PK-driven prophylaxis versus standard prophylaxis: When a tailored treatment may be a real and achievable cost-saving approach in children with severe hemophilia A Thromb Res 2017 157 58 63 10.1016/j.thromres.2017.07.003 Open DOISearch in Google Scholar

11 Lim SY, Pettit RS. Pharmacokinetic considerations in pediatric pharmacotherapy. Am J Health Syst Pharm 2019; 76(19): 1472–80. doi: 10.1093/ajhp/zxz161. LimSY PettitRS Pharmacokinetic considerations in pediatric pharmacotherapy Am J Health Syst Pharm 2019 76 19 1472 80 10.1093/ajhp/zxz161 Open DOISearch in Google Scholar